David Kerstein Selected Research

brigatinib

6/2023	Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
10/2021	Effect of severe renal impairment on the pharmacokinetics of brigatinib.
1/2021	Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer.
12/2020	Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study.
1/2020	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
1/2020	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC.
9/2019	Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
8/2019	Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).
1/2019	The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
1/2019	Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Kerstein Research Topics

Disease

11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2023 - 12/2016
4	Lung Neoplasms (Lung Cancer) 12/2020 - 10/2018
3	Neoplasms (Cancer) 01/2021 - 12/2016
3	Disease Progression 11/2018 - 08/2017
2	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2016
2	Brain Neoplasms (Brain Tumor) 10/2018 - 08/2017
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	Pulmonary Embolism 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Body Weight (Weight, Body) 01/2021
1	Exanthema (Rash) 12/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 09/2019
1	Hypertension (High Blood Pressure) 12/2016
1	Necrosis 01/2012
1	Arteriovenous Malformations (Arteriovenous Malformation) 01/2012
1	Infections 01/2012

Drug/Important Bio-Agent (IBA)

14	brigatinibIBA 06/2023 - 12/2016
11	CrizotinibIBA 01/2021 - 12/2016
10	Anaplastic Lymphoma KinaseIBA 06/2023 - 12/2016
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 12/2016
1	ponatinibIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	BilirubinIBA 01/2021
1	Amylases FDA Link 12/2020
1	Phosphotransferases (Kinase)IBA 12/2020
1	alectinibIBA 01/2019
1	ceritinibIBA 01/2019
1	Lipase (Acid Lipase)FDA Link 12/2016

Therapy/Procedure

2	Therapeutics 09/2019 - 12/2016
1	Radiotherapy 10/2018
1	Drug Therapy (Chemotherapy) 08/2017
1	Sclerotherapy 01/2012